Is there a Bearish outlook for Halozyme Therapeutics, Inc. (NASDAQ:HALO) this week?

November 10, 2018 - By Mona Holcomb

Halozyme Therapeutics, Inc. (NASDAQ:HALO) LogoInvestors sentiment decreased to 0.95 in Q2 2018. Its down 0.56, from 1.51 in 2018Q1. It fall, as 25 investors sold Halozyme Therapeutics, Inc. shares while 59 reduced holdings. 25 funds opened positions while 55 raised stakes. 118.72 million shares or 0.69% less from 119.54 million shares in 2018Q1 were reported.
Ameritas Prtn reported 0.01% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Sg Americas Secs Limited Liability Com reported 8,066 shares. Thompson Davis & Inc accumulated 0% or 125 shares. Third Security Ltd Liability reported 17.29 million shares. Colony Grp Limited Liability invested in 0.06% or 72,640 shares. 59,226 are owned by Price T Rowe Assocs Md. Farr Miller & Washington Ltd Liability Dc invested 0.07% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Blackrock, New York-based fund reported 12.24 million shares. Moreover, Renaissance Llc has 0.02% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 893,400 shares. Meeder Asset Mngmt has 5,021 shares. First Quadrant L P Ca invested in 100,933 shares. Chicago Equity Partners Lc holds 73,105 shares or 0.04% of its portfolio. Massachusetts-based Geode Capital Lc has invested 0.01% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Thrivent Financial For Lutherans reported 2.32M shares. Manufacturers Life Insur The reported 784,901 shares.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage

Among 4 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. Halozyme Therapeutics had 4 analyst reports since May 11, 2018 according to SRatingsIntel. The firm has “Market Perform” rating given on Wednesday, August 8 by BMO Capital Markets. As per Monday, May 14, the company rating was maintained by Canaccord Genuity. The firm has “Underweight” rating by Barclays Capital given on Friday, May 11. Below is a list of Halozyme Therapeutics, Inc. (NASDAQ:HALO) latest ratings and price target changes.

23/08/2018 Broker: Cantor Fitzgerald Rating: Overweight New Target: $27 Initiates Coverage On
08/08/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $19 New Target: $21 Maintain
14/05/2018 Broker: Canaccord Genuity Rating: Buy New Target: $21.0000 Maintain
11/05/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Underweight Old Target: $19 Downgrade

The stock decreased 2.22% or $0.36 during the last trading session, reaching $15.89. About 781,513 shares traded. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 32.24% since November 10, 2017 and is uptrending. It has outperformed by 16.62% the S&P500.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company has market cap of $2.28 billion. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. It has a 30.38 P/E ratio. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

More notable recent Halozyme Therapeutics, Inc. (NASDAQ:HALO) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos …” on November 06, 2018, also Nasdaq.com with their article: “Report: Exploring Fundamental Drivers Behind Entergy, BLACKLINE INC, HollyFrontier, Hill-Rom, Apache, and …” published on November 08, 2018, Benzinga.com published: “A Preview Of Halozyme Therapeutics Q3 Earnings” on November 06, 2018. More interesting news about Halozyme Therapeutics, Inc. (NASDAQ:HALO) were released by: Seekingalpha.com and their article: “Halozyme Q3 revenues $25.6M, guidance raised” published on November 06, 2018 as well as Globenewswire.com‘s news article titled: “Market Trends Toward New Normal in Halozyme Therapeutics, Fitbit, Iconix Brand Group, Leap Therapeutics …” with publication date: October 17, 2018.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: